
Silk Road Medical, Inc
SILK
Updated: 23/09/2026, 17:11:50
No historical data available
Silk Road Medical, Inc. operates as an American medical device company, focusing on innovative solutions for carotid artery disease. The firm's product portfolio is specifically engineered to support transcarotid artery revascularization (TCAR) procedures. Among its key offerings is the ENROUTE Transcarotid Neuroprotection System, designed to directly access the common carotid artery and initiate a temporary reversal of blood flow. The company also provides the ENROUTE Transcarotid Stent System, a distinctive stent characterized by its self-expanding and self-tapering capabilities. For streamlined initial entry to the common carotid artery, Silk Road Medical offers the ENHANCE Transcarotid Peripheral Access Kit. Additionally, the ENROUTE 0.014 Guidewire plays a crucial role in navigating and crossing target lesions, enabling the precise delivery of other interventional devices. Founded in 2007, Silk Road Medical, Inc. maintains its primary corporate offices in Sunnyvale, California.
No summaries found.
- Share price
- $27.49
- Market cap
- $1.12B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Charles S. McKhann
- Employees
- 474
- IPO date
- 04/04/2019
- Beta
- 1.538
- Last dividend
- $0.00
- Day range
- $27.49 – $27.50
- 52-week range
- $6.08 – $27.51
- 1-day performance
- -0.04%
- 1-year performance
- 352.14%
- Current drawdown (1Y)
- -0.07%
- CIK
- 0001397702
- CUSIP
- 82710M100
- ISIN
- US82710M1009
- Created
- 07/12/2025, 14:14:10
- Last update
- 23/09/2026, 17:11:50
Track Silk Road Medical, Inc with an AI analyst
See which prediction-market events move SILK, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
No news found for this symbol.